Rachel E. Gershman

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

Amanda Doucette, Mansoureh Rezaei, Alice McDonald, 2009, Nature.

Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays

Rachel E. Gershman, C. Claiborne, Wei Chen, 2011, Clinical Cancer Research.

Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.

Adnan O. Abu-Yousif, M. Mizutani, Courtney A. Cullis, 2021, Journal of medicinal chemistry.

Cancer Therapy : Preclinical Characterization of Alisertib ( MLN 8237 ) , an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays

Rachel E. Gershman, C. Claiborne, Wei Chen, 2011 .

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors

Suresh K Balani, Rachel E. Gershman, G. Weatherhead, 2015, ACS medicinal chemistry letters.

Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer.

Xingyue He, M. Mizutani, T. Soucy, 2021, Journal of medicinal chemistry.

Synthesis and evaluation of 4-(substituted styryl/alkenyl)-3,5-bis(4-hydroxyphenyl)-isoxazoles as ligands for the estrogen receptor.

D. Labaree, Rachel E. Gershman, R. Hanson, 2012, Bioorganic & medicinal chemistry letters.